[{"id":"3525169e-0d8d-453a-b45c-e823b8887043","acronym":"NCI-2021-10020","url":"https://clinicaltrials.gov/study/NCT05146739","created_at":"2021-12-07T13:53:26.278Z","updated_at":"2024-07-02T16:34:37.630Z","phase":"Phase 1","brief_title":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane","source_id_and_acronym":"NCT05146739 - NCI-2021-10020","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SELL","pipe":"","alterations":" ","tags":["SELL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • leucovorin calcium • fludarabine IV • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"da79fe71-e09f-48b0-9ffb-5c6b712e843b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05569512","created_at":"2022-10-06T13:55:46.803Z","updated_at":"2024-07-02T16:35:06.360Z","phase":"Phase 1/2","brief_title":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","source_id_and_acronym":"NCT05569512","lead_sponsor":"Malika Kapadia","biomarkers":" RUNX1 • HLA-DRB1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • uproleselan (APL-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-02"},{"id":"d6b17aa3-714d-42d8-af19-4fddfb8bd215","acronym":"","url":"https://clinicaltrials.gov/study/NCT04682405","created_at":"2021-01-19T20:46:55.377Z","updated_at":"2024-07-02T16:35:26.108Z","phase":"Phase 2","brief_title":"Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)","source_id_and_acronym":"NCT04682405","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • uproleselan (APL-106)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 11/11/2022","primary_completion_date":" 11/11/2022","study_txt":" Completion: 11/11/2022","study_completion_date":" 11/11/2022","last_update_posted":"2023-12-15"},{"id":"0f1545c9-469b-4469-bb95-58ad0e70086e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054543","created_at":"2021-09-23T17:53:04.550Z","updated_at":"2024-07-02T16:36:20.301Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","source_id_and_acronym":"NCT05054543","lead_sponsor":"Apollomics Inc.","biomarkers":" IDH1","pipe":"","alterations":" ","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • uproleselan (APL-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2021-11-24"},{"id":"886e3a12-de7d-497e-85b9-a4418adb4a9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04839341","created_at":"2021-04-09T16:56:14.397Z","updated_at":"2024-07-02T16:36:24.387Z","phase":"Phase 1","brief_title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","source_id_and_acronym":"NCT04839341","lead_sponsor":"Apollomics Inc.","biomarkers":" IDH1","pipe":"","alterations":" ","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • uproleselan (APL-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 02/28/2023","study_completion_date":" 02/28/2023","last_update_posted":"2021-09-15"}]